Form 4: Clover Health CEO Jamie L. Reynoso Reports Acquisition of Class A Common Stock
SEC Form 4 Filing
Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health Investments, reports acquiring shares of Class A Common Stock through a restricted stock unit award.
Summary
- On October 15, 2024, Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health Investments, acquired 726,114 shares of Class A Common Stock.
- These shares were obtained through a time-based restricted stock unit (RSU) award.
- The RSUs vest 25% on the first anniversary of the grant date (October 15, 2024), with the remaining RSUs vesting in equal quarterly installments over the following three years, contingent upon continued service.
- Following the transaction, Reynoso directly owns 3,471,853 shares of Class A Common Stock.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The acquisition of shares by the CEO indicates confidence in the company, but it's a routine transaction related to compensation.
Positives
- The CEO's acquisition of shares demonstrates confidence in the company's future prospects.
- The vesting schedule of the RSUs incentivizes long-term commitment from the CEO.
Future Outlook
The vesting schedule of the RSUs suggests an expectation of continued service and commitment from the CEO over the next four years.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which is important for investor confidence in the healthcare sector.
Comparison to Industry Standards
- Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
- Vesting schedules are a common mechanism to ensure long-term commitment from executives.
- The specific terms of Reynoso's RSU award (vesting schedule, etc.) would need to be compared to those of executives at comparable healthcare companies to assess its competitiveness.
Stakeholder Impact
- The CEO's increased stake in the company could positively influence shareholder confidence.
- The vesting schedule incentivizes the CEO to focus on long-term value creation, benefiting shareholders.
Key Dates
| Date | Description |
|---|---|
| 10/15/2024 | Date of earliest transaction and grant date of restricted stock units (RSUs). |
| 10/15/2024 | First vesting date for 25% of the RSUs. |
| 10/15/2028 | Final vesting date for the RSUs. |
| 10/17/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.